Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 16 years of Other Non Operating Income data on file, last reported at -$1.6 million in Q1 2026.

• Quarterly Other Non Operating Income fell 467.35% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 299.37% YoY) and the FY2025 annual result came in at $5.3 million, up 400.86% from the prior year.
• Other Non Operating Income eased to -$1.6 million in Q1 2026, from $277000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $4.7 million in Q3 2025 to a low of -$3.1 million in Q3 2024.
• A 5-year average of $305235.3 and a median of $306000.0 in 2023 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 2262.5% in 2024, down 534.87% in 2024.
• Tracing ARWR's Other Non Operating Income over 5 years: stood at $507000.0 in 2022, then retreated by 16.96% to $421000.0 in 2023, then decreased by 19.0% to $341000.0 in 2024, then decreased by 18.77% to $277000.0 in 2025, then plunged by 680.87% to -$1.6 million in 2026.
• The last three Other Non Operating Income figures came in at -$1.6 million (Q1 2026), $277000.0 (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.